Floatz logo

Tuvonralimab

Regorafenib

JIANG LONGWEIEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Regorafenib cohort.

Asset / SponsorPhaseRating
Regorafenib
M.D. Anderson Cancer Center
Phase 3BB
Irinotecan
Sun Yat-sen University
Phase 3B
Lorigerlimab
M.D. Anderson Cancer Center
Phase 2CCC
Raltitrexed
China Medical University, China
Phase 1/2CC
Iparomlimab
JIANG LONGWEI
Early Phase 1C

View all 9 →

Same molecule, other indications

Tuvonralimab is also rated in:

CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
autoimmune pulmonary disease due to PD-1 deficiencyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →